These results suggest that inhibiting TRIP4 may be a new therapeutic approach for cervical cancer therapy that specifically targets the P13K/AKT and MAPK/ERK pathways as well as the hTERT pathways in cervical cancer cells. The gene discussed is TRIP4; the disease is cervical cancer.